Tinzapari (Innohep)
Supportive Care · Approved since 2000
Description
Tinzaparin is a low molecular weight heparin (LMWH) anticoagulant used for venous thromboembolism prophylaxis in colorectal cancer patients. It serves as supportive care to prevent blood clots in patients with metastatic colorectal cancer and those undergoing surgical resection. This medication addresses the increased thrombotic risk associated with cancer and cancer treatments, particularly in the perioperative period.
Mechanism of Action
Tinzaparin works by binding to antithrombin III, enhancing its ability to inactivate coagulation factors Xa and IIa (thrombin). This mechanism prevents the formation of fibrin clots by interrupting the coagulation cascade at multiple points, with preferential inhibition of factor Xa over thrombin.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Innohep |
| Category | Supportive Care |
 Status | FDA Approved |
| Administration | Subcutaneous |
| Year Approved | 2000 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.